ArticleJournal of emergencies, trauma, and shock
Clinical Outcomes of High-dose Intravenous Nitroglycerin in Sympathetic Crashing Acute Pulmonary Edema.
Article in Journal of emergencies, trauma, and shock. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Sympathetic Crashing Acute Pulmonary Edema (SCAPE) is a life-threatening form of acute heart failure requiring immediate management with noninvasive ventilation (NIV) and vasodilator therapy. Although nitroglycerin (NTG) is commonly used, optimal dosing remains uncertain. Emerging evidence suggests high-dose NTG may provide rapid clinical improvement. We aimed to evaluate the safety and efficacy of high-dose intravenous NTG in patients presenting with SCAPE to the emergency department (ED). Methods: We conducted a prospective observational study in a high-volume, busy ED, enrolling adults (>18 years) meeting established diagnostic criteria for SCAPE who received an initial intravenous NTG bolus ≥400 μg. Patients with acute coronary syndrome, trauma, recent phosphodiesterase V inhibitor use, or significant aortic stenosis were excluded. Clinical status and outcomes were assessed at 3, 6, and 12 h, and at ED disposition. The primary objective was clinical outcomes (symptom resolution, need for intubation, and ED disposition) of SCAPE patients. Results: Sixty-one patients were included. The mean NTG bolus dose was 830 μg. One patient (1.6%) developed hypotension requiring fluids and brief inotropic support. Headache occurred in five patients (8.2%). Symptom resolution was observed in 10 patients (16%) at 3 h, 32 (52.5%) at 6 h, and 55 (90%) at 12 h. Five patients (8.2%) required intubation. Overall, 41 patients (67.2%) were discharged directly from the ED. The mean ED length of stay was 14 h. Conclusion: High-dose intravenous NTG may improve clinical outcomes in the acute management of SCAPE, with rapid symptom resolution and reduced need for intubation. Larger studies are warranted to confirm these findings and to standardise dosing protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.